A Look at Travere Therapeutics's Valuation Following Positive FILSPARI Results Presented at ASN Kidney Week 2025

Travere Therapeutics shared new results at the upcoming ASN Kidney Week 2025, showing that its FILSPARI treatment led to greater and more consistent proteinuria reduction compared to current options. The presentation also emphasized positive biomarker and cardiovascular safety data.

See our latest analysis for Travere Therapeutics.

After unveiling new FILSPARI data ahead of ASN Kidney Week, Travere Therapeutics has seen positive momentum reflected in its stock, with a 15.5% 1-month share price return and a 52.9% total shareholder return over the past year. Investors seem to be responding to renewed confidence in the pipeline and underlying growth potential.

If this kind of biotech progress has you curious about broader opportunities, uncover new possibilities for your portfolio with our See the full list for free.

With shares trading at around 27 dollars and a notable discount to analysts' price targets, investors may be questioning whether the market is underestimating Travere's growth prospects or if Wall Street has already factored in next year’s potential gains.

Most Popular Narrative: 23.5% Undervalued

With Travere Therapeutics closing at $27.32 and the most widely followed narrative setting fair value at $35.71, there is a substantial gap that captures attention. This setup reflects both optimism for long-term potential and the weighty expectations riding on FILSPARI’s expansion and growth.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market. If approved, this will create a new, high-margin revenue stream and significantly expand the company's addressable market. (Revenue growth, gross margins)

Read the complete narrative.

Curious how a potential shake-up in rare disease treatments gave rise to a bold price target? This narrative banks on blockbuster growth, sharply rising profit margins, and profitability levels that defy the company’s history. Want to know which future milestones the analysts see as key? See what’s driving the bullish outlook in the full breakdown.

Result: Fair Value of $35.71 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, rising competition in rare kidney disease therapies and Travere’s heavy reliance on FILSPARI could quickly change the bullish outlook if challenges emerge.

Find out about the key risks to this Travere Therapeutics narrative.

Build Your Own Travere Therapeutics Narrative

Prefer to draw your own conclusions or challenge the consensus? You can quickly craft your personalized analysis and shape your outlook in just minutes. Do it your way

A great starting point for your Travere Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Unlock your next smart move by checking out breakthrough stocks and trends. These carefully selected ideas offer standout potential and unique opportunities you won’t want to miss.

• Tap into the income potential of reliable companies by seeing these 18 dividend stocks with yields > 3% posting yields above 3 percent.
• Spot the innovators reshaping healthcare through artificial intelligence with these 33 healthcare AI stocks, connecting you to pioneers blending science and technology.
• Gain an edge on tomorrow’s market leaders by tracking these 24 AI penny stocks making headlines in powerful machine learning and automation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com